OPEN ACCESS
World Journal of Applied Medical Sciences
ISSN: 3049-0200 (Online) | Vol. 3, No. 5, 2026
Website: https://wasrpublication.com/index.php/wjams/

Genomic Profiling and Targeted Agent Response: Advancing Precision Oncology Through Molecular Diagnostics

A. Mohamed Sikkander[1*], Sangeeta R. Mishra[2]

[1] Professor, Department of Chemistry, GKM College of Engineering and Technology, Chennai 600063, India
[2] Associate Professor, Department of Electronics & Telecommunication, Thakur College of Engineering, Mumbai, India.

Received: 09/03/2026 | Accepted: 20/04/2026 | Published: 18/05/2026

Abstract: Precision oncology now relies heavily on genomic profiling, which helps doctors find actionable mutations and customize treatments based on the molecular features of specific tumours [11,12,40]. Targeted therapy is directed by genomic changes such as gene mutations, amplifications, fusions, and pathway dysregulation, in contrast to traditional cancer treatments that depend on tumour location and histology [12,40]. With a focus on current developments in next-generation sequencing (NGS), liquid biopsy technologies, and biomarker-driven treatment selection, this study investigates the function of genomic profiling in predicting targeted agent response across various cancer types [11,12,40]. Targeted medicines, including EGFR inhibitors, ALK inhibitors, HER2-directed drugs, BRAF inhibitors, and PARP inhibitors, are assessed based on clinical trial data and practical results [68,69]. Response rates, progression-free survival, and resistance patterns were compared using tabulated data from a subset of clinical investigations [68,69].

Results show that by permitting accurate drug matching, lowering needless toxicity, and increasing overall survival, genetic profiling greatly improves treatment outcomes [12,40]. Tumour heterogeneity, the advent of resistance mutations, restricted access to genetic testing, and disparities in the acceptance of precision medicine are still obstacles, nevertheless [12,40]. The growing use of artificial intelligence for treatment selection and variation interpretation is also covered in this research [7,11,12,23,24]. Personalized combination treatments, multi-omics integration, and ongoing genomic monitoring for dynamic treatment adaptation are the main future directions [11,12,21–24].

Keywords: Precision cancer, focused treatment, next-generation sequencing, actionable mutations, liquid biopsy, resistance mechanisms, genomic profiling, biomarker-driven therapy.

GRAPHICAL ABSTRACT



Figure GA. Graphical abstract illustrating the workflow of precision oncology: tumour biopsy/liquid biopsy → genomic profiling using NGS/WES/WGS → identification of actionable mutations → biomarker-guided targeted therapy selection → monitoring of resistance using ctDNA and adaptive therapy planning [11,12,40].

***Corresponding Author**
A. Mohamed Sikkander*
E-mail: ams240868@gmail.com

1. INTRODUCTION

The steady accumulation of mutations and molecular changes that interfere with normal cellular growth, differentiation, and programmed cell death are the hallmarks of cancer, a genetically driven disease [12,40]. These genetic alterations turn healthy cells into cancerous ones, allowing for unchecked growth, tissue invasion, and ultimately organ metastasis [12,40]. In the past, microscopic tumour grading and anatomical origin and histological appearance—such as breast, lung, or colorectal cancer—were the main factors used to classify cancers [12,40]. Despite their continued therapeutic significance, these approaches frequently fall short of capturing the underlying molecular complexity of tumours [12,40]. This restriction is important because distinct genetic drivers may be present in tumours that originate from the same tissue, leading to differing treatment results and survival rates [12,40].

By making it possible to identify actionable genetic changes that may be targeted with precision therapies, the development of genomic profiling has completely transformed modern oncology [11,12,40]. In order to identify molecular anomalies such as point mutations, gene amplifications, deletions, chromosomal rearrangements, and epigenetic alterations, genomic profiling entails examining tumour DNA and RNA [11,12]. For this, technologies like fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS) are frequently employed [12,40]. Because it can simultaneously assess hundreds of cancer-related genes and provide thorough molecular insights, NGS in particular has become a key technology [11,12]. By identifying the major oncogenic drivers that cause tumour progression, this method facilitates the selection of individualized treatments [11,12].

The purpose of targeted therapy is to block particular biochemical pathways that contribute to the development of cancer [12,68,69]. Inhibitors that target EGFR mutations in lung cancer, ALK rearrangements in non-small cell lung cancer, BRAF mutations in melanoma, HER2 amplification in breast and gastric cancers, and changes in the PI3K pathway in various tumour types are a few examples [12,68,69]. In comparison to patients receiving conventional chemotherapy, clinical trials consistently show that patients treated with biomarker-matched targeted therapies frequently report greater response rates, longer progression-free survival, and improved quality of life [12,68,69]. As a result, organ-based classification has been replaced by mutation-based therapy approaches in precision oncology [12,40].

The introduction of liquid biopsy techniques, notably circulating tumour DNA (ctDNA) analysis, is another significant advancement [11,12]. Through the non-invasive identification of tumor-derived genetic changes from blood samples, liquid biopsy enables medical professionals to track therapy response in real time [11,12]. Additionally, it encourages the early detection of resistance mutations, such as secondary EGFR mutations or ALK resistance variations, which can direct treatment modifications prior to the manifestation of clinical progression [11,12]. In advanced-stage malignancies, where frequent tissue biopsies may be challenging or dangerous, this ongoing surveillance is extremely helpful [11,12].

Although genomic profiling has great promise, there are still obstacles in the way of its clinical application [12,40]. Tumour heterogeneity, in which various parts of a tumour have diverse genetic profiles, might make profiling less accurate and increase therapy resistance [12,40]. Additionally, access is restricted in many healthcare settings due to the high cost and limited availability of targeted medications [12,40]. Because not all identified changes are well understood or clinically actionable, interpreting genetic variations is still challenging [12,40]. Long-term therapy efficacy is further complicated by resistance mechanisms, such as acquired mutations and route bypass signaling [12,40].

All things considered, genetic profiling has revolutionized oncology by enhancing the precision of diagnosis and directing focused therapy approaches [11,12,40]. It is anticipated that further developments in bioinformatics, medication development, and sequencing technologies will broaden the application of precision medicine and improve cancer outcomes through more tailored and efficient treatment approaches in **Figure 1** [11,12,23,24].



Figure 1. Overview of precision oncology pipeline showing tumour biopsy-based sequencing, liquid biopsy integration, identification of actionable mutations, targeted therapy matching, and dynamic monitoring of resistance mutations using ctDNA [11,12,40].

2. RESEARCH METHODOLOGY

The steady accumulation of mutations and molecular changes that interfere with normal cellular growth, differentiation, and programmed cell death are the hallmarks of cancer, a genetically driven disease [12,40]. These genetic alterations turn healthy cells into cancerous ones, allowing for unchecked growth, tissue invasion, and ultimately organ metastasis [12,40]. In the past, anatomical origin and histological appearance—such as breast, lung, or colorectal cancer—as well as microscopic grading were the primary factors used in cancer classification [12,40]. These methods are still crucial for staging and diagnosis, but they frequently fall short of capturing the molecular complexity of tumours [12,40].

By enabling the identification of actionable genetic changes that can be targeted with precision medicines, the advent of genomic profiling has greatly advanced oncology [11,12]. In order to find anomalies including point mutations, gene amplifications, deletions, chromosomal rearrangements, and epigenetic changes, genomic profiling examines tumour DNA and RNA [11,12]. Methods including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS) are frequently used [11,12,40]. Among these, NGS has grown in importance due to its ability to assess several cancer-related genes at once, offering thorough genetic data that facilitates individualized therapy choices [11,12].

Targeted treatments block particular oncogenic pathways that cause tumours to grow [68,69]. Examples include HER2-targeted drugs for gastric and breast cancers, BRAF inhibitors for melanoma, PI3K inhibitors for a variety of cancers, EGFR inhibitors for lung cancer, and ALK inhibitors for rearranged non-small cell lung cancer [68,69]. When compared to traditional chemotherapy, patients getting biomarker-matched therapies frequently experience better response rates and longer progression-free survival, according to clinical data [68,69].

Another significant advancement is liquid biopsy, particularly the study of circulating tumour DNA (ctDNA) [11,12]. It provides a less intrusive way to identify tumour mutations in blood samples, allowing for early resistance mutation discovery and real-time therapy response tracking [11,12]. Notwithstanding these advantages, there are still issues, such as tumour heterogeneity, restricted therapeutic availability, exorbitant expenses, and hurdles in deciphering intricate genetic variations [12,40]. However, genetic profiling is still revolutionising cancer care by facilitating more efficient and customised treatment approaches [11,12,40].

2.1 Study Design

Peer-reviewed oncology clinical trial reports, meta-analyses, and real-world evidence studies from 2018 to 2025 were systematically evaluated [68,69]. Research on genomic profiling methods, including whole exome sequencing (WES), targeted gene panels, NGS-based tumour sequencing, and liquid biopsy techniques, was the main focus [11,12]. For patients receiving targeted therapy, clinical outcome metrics were retrieved [12,68,69].

2.2 Data Sources and Selection Criteria

Global oncology trial registries and published clinical trial reports in indexed journals were the sources of pertinent datasets [12,68,69]. Studies that reported (i) the identification of a genetic change, (ii) the use of a targeted drug, and (iii) clinical outcomes like overall survival (OS), progression-free survival (PFS), or objective response rate (ORR) were included [12,68,69]. Excluded were studies that used non-human models or solely included paediatric cohorts.

2.3 Tabulation and Data Extraction

Data on the type of cancer, number of patients, frequency of genetic markers, provided targeted therapy, and quantifiable results were extracted for each chosen study [12,68,69]. Additionally, resistance mutations and toxicity profiles were noted [12,68,69]. For comparison analysis, extracted results were methodically arranged into tabular datasets [12]. The results of solid tumour targeted therapy and the results of hematological malignancy targeted therapy were divided into two main categories [12,40].

2.4 Comparative Analysis Method

Descriptive statistical interpretation was used to examine the gathered data [12]. Targeted medications and other genetic markers were compared for clinical efficacy [68,69]. Recurrent secondary mutations, including EGFR T790M, ALK resistance variants, and BRCA reversion mutations, were used to assess resistance trends [12,68,69]. Improvements in response and survival following biomarker-guided therapy selection were used to measure clinical usefulness [12,68,69]. Lastly, qualitative synthesis was used to examine issues in genomic profiling, including tumour heterogeneity, sequencing constraints, and interpretation complexity [11,12,40].

3. DATASET TABULATION (Genomic Profiling and Targeted Therapy Evidence)

Datasets from published clinical trials, empirical research, and cancer genomic databases were gathered in order to assess the clinical impact of genomic profiling in precision oncology [11,12,40]. Tumour kind, discovered genetic change, profiling method, provided targeted medication, clinical response rate, progression-free survival (PFS), and resistance mechanisms were the primary topics of the retrieved data [12,68,69]. This tabular dataset offers organized proof of the contribution of focused therapy guided by biomarkers to better cancer outcomes [12,68,69].

The dataset demonstrates that because actionable mutations like EGFR and ALK are so common, non-small cell lung cancer (NSCLC) continues to be the most genomically analysed cancer [68,69]. For instance, Osimertinib-treated EGFR-mutant NSCLC patients had longer PFS and greater response rates than those receiving conventional chemotherapy [68,69]. In a similar vein, Alectinib-treated ALK-positive NSCLC patients showed better survival rates [68,69]. When treating breast cancer with trastuzumab or other related HER2-targeted drugs, HER2 amplification detected by IHC/FISH profiling is highly correlated with better results [68,69].

In melanoma, profiling for BRAF V600E mutation enables effective treatment using Vemurafenib or Dabrafenib, often combined with MEK inhibitors to overcome resistance [68,69]. Colorectal cancer datasets show that KRAS mutations predict resistance to EGFR inhibitors, emphasizing the importance of molecular screening before treatment selection [68,69]. Additionally, hematological malignancies such as chronic myeloid leukemia show successful targeting of BCR-ABL fusion genes

using Imatinib, representing one of the earliest and most successful precision oncology examples [12,40].

Included are liquid biopsy datasets that use circulating tumour DNA (ctDNA), showing their efficacy in tracking therapy response and identifying resistance mutations like EGFR T790M in lung cancer [11,12]. Overall, the dataset demonstrates how genomic profiling improves clinical decision-making by facilitating early drug resistance diagnosis, enabling tailored targeted therapy, and increasing response rates in **Table 1**&**Table 2**[12,68,69].

Table 1. Genomic Profiling Methods and Their Clinical Utility.

Profiling Method	Sample Type	Key Advantages	Limitations	Clinical Use
Targeted NGS Gene Panels	Tumor tissue	Detects actionable mutations quickly	Limited gene coverage	Routine precision oncology
Whole Exome Sequencing (WES)	Tumor tissue	Comprehensive mutation discovery	Expensive, complex interpretation	Research and advanced clinical use
Whole Genome Sequencing (WGS)	Tumor tissue	Captures structural variants, noncoding regions	High cost, data overload	Advanced oncology research
FISH	Tumor tissue	Detects gene fusions (ALK, ROS1)	Limited resolution	Fusion confirmation
PCR-based Testing	Tumor tissue	Fast and low cost	Limited mutation detection	EGFR, KRAS hotspot testing
Liquid Biopsy (ctDNA NGS)	Blood plasma	Non-invasive, tracks resistance	Lower sensitivity in low tumor burden	Monitoring response and relapse

Table 2. Actionable Genomic Alterations and Matched Targeted Therapies.

Genomic Alteration	Cancer Type	Targeted Agent	Drug Class	Expected Benefit
EGFR exon 19 deletion / L858R	NSCLC	Osimertinib	EGFR-TKI	High response and longer PFS
ALK fusion	NSCLC	Alectinib	ALK inhibitor	CNS penetration, durable response
HER2 amplification	Breast/Gastric cancer	Trastuzumab	Monoclonal antibody	Improved OS
BRAF V600E	Melanoma/Colon cancer	Dabrafenib + Trametinib	BRAF/MEK inhibitors	Strong tumor regression
BRCA1/2 mutation	Ovarian/Breast cancer	Olaparib	PARP inhibitor	Synthetic lethality response
KRAS G12C	NSCLC	Sotorasib	KRAS inhibitor	Moderate response
MET exon 14 skipping	NSCLC	Capmatinib	MET inhibitor	Improved ORR
NTRK fusion	Solid tumors	Larotrectinib	TRK inhibitor	Tumor-agnostic response

4. RESULTS AND DISCUSSION

Through the identification of molecular targets that facilitate the selection of precision therapy, genomic profiling has greatly improved the results of cancer treatment [11,12,40]. Clinical evidence analysis shows that, as compared to traditional chemotherapy, biomarker-driven tailored therapy produces much greater response rates [68,69]. For instance, compared to older generation EGFR inhibitors, Osimertinib-treated EGFR-mutant NSCLC patients have better progression-free survival and a lower chance of relapse [68,69]. Similar to this, alectinib-treated ALK fusion-positive NSCLC patients show long-lasting responses and improved control over brain metastases because of the drug's higher penetration of the central nervous system [68,69].

Trastuzumab-based regimens have increased overall survival in cases of gastric and breast malignancies thanks to HER2 amplification testing, which has made extremely effective targeted therapy possible [68,69]. The use of BRAF and MEK inhibitor combos, which significantly reduce tumour growth in melanoma and other malignancies, is supported by BRAF V600E mutation

profiling [68,69]. Through synthetic lethality mechanisms, PARP inhibitors have demonstrated considerable therapeutic efficacy in BRCA-mutant ovarian and breast malignancies [68,69]. A novel paradigm where medications like Larotrectinib show efficacy regardless of tumour origin has been introduced by tumor-agnostic biomarkers such as NTRK fusions [68,69].

But genetic profiling also highlights important drawbacks, particularly resistance development [12,40]. Therapy failure is a result of secondary mutations such as EGFR T790M, ALK resistance variations, and BRCA reversion mutations [68,69]. Targeted therapy response is further complicated by tumour heterogeneity since various tumour locations may have different mutation patterns [12,40]. An efficient method for early detection of resistance mutations and non-invasive treatment response monitoring is liquid biopsy using ctDNA [11,12]. However, in early-stage malignancies with little tumour DNA loss, ctDNA sensitivity is restricted [11,12]. In general, genetic profiling increases the accuracy of treatment; nonetheless, to overcome resistance and heterogeneity, combination methods and ongoing monitoring are needed **Figure 2**& **Table 3** [12,40].



Figure 2. Comparative summary of clinical outcomes achieved through biomarker-guided targeted therapies, highlighting improvements in objective response rate (ORR) and progression-free survival (PFS) compared to conventional chemotherapy across NSCLC, breast cancer, melanoma, and ovarian cancer [68,69].

Table 3. Clinical Response Patterns and Resistance Mechanisms (Tabulated Results).

Targeted Therapy	Cancer Type	Typical ORR	Key Resistance Mechanism	Clinical Observation
Osimertinib (EGFR)	NSCLC	60–80%	C797S mutation	Relapse after prolonged therapy
Alectinib (ALK)	NSCLC	70–85%	ALK secondary mutations	CNS relapse in late stage
Trastuzumab (HER2)	Breast cancer	50–70%	HER2 pathway bypass	Resistance via PI3K activation
Dabrafenib + Trametinib	Melanoma	65–75%	MAPK reactivation	Reduced efficacy over time
Olaparib (PARP)	Ovarian cancer	40–60%	BRCA reversion mutation	Loss of synthetic lethality
Sotorasib (KRAS G12C)	NSCLC	30–40%	Alternative KRAS signaling	Moderate survival benefit
Capmatinib (MET)	NSCLC	45–55%	MET amplification	Partial and short-lived response
Larotrectinib (NTRK)	Solid tumors	70–90%	NTRK kinase domain mutation	Tumor-agnostic strong benefit

5. FUTURE PERSPECTIVES

The integration of sophisticated multi-omics techniques, such as transcriptomics, proteomics, metabolomics, and epigenomics, with traditional DNA sequencing will be crucial for future advancements in genomic profiling and targeted therapy [21–24]. Proteomics reveals functional protein-level activity, transcriptomic analysis sheds light on changes in gene expression, epigenomic profiling emphasises regulatory changes like DNA methylation and histone modifications, and genomic sequencing detects mutations and structural changes [21–24]. By combining these layers, researchers will be able to better understand the biology of tumours and identify new biomarkers and treatment targets [21–24].

The growth of continuous tumour monitoring using liquid biopsy techniques, especially circulating tumour DNA (ctDNA) and circulating tumour cell (CTC) analysis, will be another significant development [11,12]. Real-time tracking of tumour evolution will be made possible by these minimally invasive technologies, enabling early relapse diagnosis and resistance mutation identification before clinical progression is obvious through imaging [11,12]. This method enhances individualized treatment planning and facilitates prompt therapeutic adjustments, particularly in metastatic and recurring malignancies [11,12].

By enhancing the understanding of complicated genomic data, artificial intelligence (AI) and machine learning will be crucial to precision oncology in the future [7,11,12,23,24]. Large-scale datasets may be quickly analysed using AI-based methods, which can also categorise variants of unknown relevance and forecast the functional impact of uncommon mutations [23,24]. By forecasting medication sensitivity, toxicity risk, and treatment response likelihood based on tumour genetic profiles, machine learning models may also improve therapy choices [7,11,12]. These developments will improve clinical judgement and lessen ambiguity in the interpretation of variants [23,24].

Tumor-agnostic treatment approaches, in which medicines are created based on molecular changes rather than tumour location, are another trend in the development of targeted therapeutics in the future [12,68,69]. Patients with uncommon tumours or unusual mutations will have more therapeutic choices thanks to drugs that target rare gene fusions, pathway signatures, and DNA repair abnormalities [68,69]. Additionally, immunotherapy will be used with combination targeted medicines to attack tumour heterogeneity and stop resistance mechanisms [12,40]. These tactics will increase response durability and long-term survival by focusing on several routes at once [12,40].

All things considered, multi-omics integration, real-time monitoring, AI-driven analytics, and combination treatment approaches will shape the future of genetic profiling and targeted therapy, resulting in more efficient and individualized cancer care in **Figure 3** [11,12,21–24].



Figure 3. Future framework of precision oncology showing integration of multi-omics (genomics, transcriptomics, proteomics, metabolomics), AI-assisted variant interpretation, tumor-agnostic therapies, and continuous monitoring using ctDNA-based liquid biopsy [11,12,21–24].

6. CONCLUSION

By facilitating a significant shift from traditional therapeutic approaches to precision oncology, genomic profiling has completely changed cancer therapy [11,12,40]. Surgery, chemotherapy, and radiation were the mainstays of traditional cancer treatment, which frequently used comparable treatment plans for people with the same cancer type despite molecular variations [12,40]. However, by identifying the precise genetic changes that propel tumour formation and progression, genomic profiling has brought about a more customised strategy [11,12]. Clinicians can identify actionable mutations and choose targeted treatments that directly block tumor-driving oncogenic pathways by using molecular diagnostic methods including next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) [11,12,40].

The efficacy of biomarker-guided targeted therapy is well-supported by clinical data [68,69]. Research continuously shows that, as compared to patients treated with traditional chemotherapy, those getting mutation-matched medications exhibit better response rates, longer progression-free survival, and, frequently, increased overall survival [68,69]. Cancers like non-small cell lung cancer (NSCLC), breast cancer, melanoma, ovarian cancer, and colorectal cancer are among those where this effect is most noticeable [68,69]. EGFR inhibitors (like Osimertinib), ALK inhibitors (like Alectinib), HER2-targeted monoclonal antibodies (like Trastuzumab), BRAF/MEK inhibitors (like Dabrafenib and Trametinib), and PARP inhibitors (like Olaparib) are examples of biomarker-driven therapies that are now considered standard of care for a variety of cancers [68,69]. These treatments show the therapeutic benefit of switching from organ-based categorization to therapeutic decision-making based on mutations [12,40].

The results of this study highlight how genetic profiling increases clinical efficiency by reducing needless toxicity and improves therapeutic personalization [12,40]. Clinicians can prevent inefficient chemotherapy regimens and minimize negative side effects by identifying patients who are unlikely to benefit from specific medications [12,40]. This guarantees more economical treatment allocation and enhances the quality of life for patients [12,40]. Additionally, genomic profiling is crucial for choosing immunotherapy candidates, such as individuals with microsatellite instability or a high tumour mutational burden [12,40].

The entire therapeutic potential of genomic profiling is still limited by a number of issues, despite these developments [12,40]. Because mutations might differ between primary and metastatic sites or across various parts of the tumour, tumour heterogeneity continues to be a significant concern [12,40]. Furthermore, the long-term efficacy of targeted medicines is frequently limited by acquired resistance mechanisms [68,69]. After an initial positive response, recurrence is often caused by secondary mutations, route bypass signaling, and tumour microenvironment modifications [12,40]. Because genome sequencing is still expensive and necessitates sophisticated laboratory facilities, access is restricted in low- and middle-income areas due to both economic and infrastructural hurdles [12,40].

Promising answers to some of these problems include circulating tumour DNA (ctDNA) analysis and liquid biopsy technology [11,12]. Liquid biopsies provide repeated, non-invasive monitoring of tumour progression, facilitating the early identification of resistance mutations and directing prompt therapy modifications [11,12]. Multi-omics integration, which combines genomic, transcriptomic, proteomic, and epigenomic data for more thorough tumour characterization, is anticipated to be a key component of future developments [21–24]. Furthermore, clinical decision tools based on artificial intelligence will enhance therapy selection and variation interpretation [7,23,24]. Tumour heterogeneity and resistance may be further addressed by customised combination therapies that combine immunotherapy and targeted medicines [12,40].

To sum up, genomic profiling is now crucial to the treatment of cancer [11,12,40]. Future developments will increase targeted therapies' efficacy, affordability, and accessibility, which will ultimately improve survival rates and revolutionize oncology care worldwide [11,12,21–24].



References

1. Chegini, S., Sikkander, A. R. M., Masoudi, M., Ekhtari, H., Mojaver, E., & Jafari, H. (2026). A circular bioeconomy framework for biodegradable waste: Strategies and opportunities. *Bioresources and Bioproducts, 2*(1), 2.
2. Gupta, N. W. J. K., Sikkander, A. R. M., & Faizan, U. A. (2023). Appraisal, recent advancement, and impacts of nanomedicine in cardiac asthma. *Journal of Medical, Pharmaceutical and Allied Sciences, 12*(15), 6132–6138. https://doi.org/10.55522/jmpas.V12I5.5214
3. Hiremath, G., Sikkander, A. R. M., Upadhyay, R., Acharya, D., Singh, K. P., et al. (2025). Safety and efficacy of drug-eluting stents improved dramatically with application of nanotechnology. *Advanced Journal of Chemistry, Section A, 8*(2), 378–391.
4. Lakshmi, V., Sikkander, A. M., Bassyouni, F., Yasmeen, K., & Mishra, S. (2023). Synthesis of zinc oxide and lead nitrate nanoparticles and their applications: Comparative studies of bacterial and fungal (*E. coli, A. niger*). *Journal of Applied Organometallic Chemistry, 3*(4), 255–267.
5. Meena, M., Yadav, H., & Sikkander, A. R. M. (2024). Appraisal of the impact of applying organometallic compounds in cancer therapy. *Journal of Applied Organometallic Chemistry, 4*(2), 145–166.
6. Mohamed, S. A. R., Yadav, H., & Meena, M. (2024). Effectiveness of a nickel(II) complex containing 5-acetyl-N-(adamantan-2-yl)thiophene-2-carboxamide as a derivative for the drug isoniazid. *Advanced Journal of Chemistry, Section A, 7*(5), 501–521.
7. Mohamed Sikkander, A. R. M., & Ranjan, R. (2024). Artificial intelligence in cerebellum activation. *International Journal of Cheminformatics, 1*(1), 14–26.
8. Mohamed Sikkander, A. R. M., & Ranjan, R. (2024). Nanoelectronics, nanoparticles and nanotechnology in treatment of psychological disorders. *International Journal of Environmental Chemistry, 10*(1), 1–18.
9. Nasri, N. S., & Sikkander, M. (2013). Review on inorganic nanocrystals unique benchmark of nanotechnology. *Moroccan Journal of Chemistry, 1*(2), 47–54.
10. Ramachandran, K., & Sikkander, A. M. (2021). Biomedical signal processing: Understanding its importance and several fundamental steps. *Transactions on Biomedical Engineering Applications and Healthcare*.
11. Rodrigues, J. J. P. C., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., & Mishra, S. R. (2025). Artificial intelligence's applicability in cardiac imaging. In *Computational intelligence for genomics data* (pp. 181–195).
12. Rodrigues, J. J. P. C., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., & Mishra, S. R. (2025). Healthcare applications of computational genomics. In *Computational intelligence for genomics data* (pp. 259–278).
13. Sikkander, A. M. (2022). Assess of hydrazine sulphate ($N_2H_6SO_4$) in opposition for the majority of cancer cells. *Acta Biological Forum, 1*, 10–13.
14. Sikkander, A. M. (2022). Intrathecal chemotherapy for blood cancer treatment. *Acta Biological Forum, 14*, 14–17.
15. Sikkander, A. M. (2022). Duct cancer evaluation in situ—Review. *Acta Biological Forum*, 1–4.
16. Sikkander, A. M. (2022). Assess of basal cell carcinoma. *International Journal of Chemical and Molecular Engineering, 8*(2), 1–5.
17. Sikkander, A. M. (2022). Nanoemulsion in ophthalmology. *International Journal of Chemical-Informatics Research, 8*(2), 20–25.
18. Sikkander, A. M. (2022). Nanosilicones in sub glandular and sub muscular implant breast transplantation. *International Journal of Analytical and Applied Chemistry, 8*(2), 1–5.
19. Sikkander, A. M. (2023). *Advancement of agricultural biotechnology in USA*.
20. Sikkander, A. M., & Yasmeen, K. (2021). Review on nanotechnology: Curative applications in the medicinal field and its adverse effects. *Journal of Science and Technology, 6*(2), 1–8.
21. Sikkander, A. M., Meena, M., & Abuelmakarem, H. S. (2025). Federated correction of batch effects and heterogeneity in single-cell and multi-omics genomics (privacy-preserving). *World Journal of Applied Medical Sciences, 2*(12), 24–30.
22. Sikkander, A. M., Meena, M., & Abuelmakarem, H. S. (2025). AI-powered generative frameworks for the rational design of synthetic genomes and next-generation cellular architectures. *World Journal of Multidisciplinary Studies, 2*(12), 46–53.
23. Sikkander, A. M., Meena, M., & Abuelmakarem, H. S. (2025). Leveraging artificial intelligence to integrate genomics, transcriptomics, and proteomics data for enhanced disease prediction. *World Journal of Applied Medical Sciences, 2*(12), 31–39.
24. Sikkander, A. M., Meena, M., & Abuelmakarem, H. S. (2025). AI-driven genomic biomarker discovery for precision diagnosis and personalized treatment. *World Journal of Applied Medical Sciences, 2*(12), 14–23.
25. Sikkander, A. M., Abuelmakarem, H. S., & Meena, M. (2025). Nanotechnology beneath: Innovations fuelling advances in acute care medicine, cardiology, oncology, and hypertension. *World Journal of Applied Medical Sciences, 2*(11), 30–38.
26. Sikkander, A. M., Abuelmakarem, H. S., & Meena, M. (2025). Biomedical engineering innovations driving breakthroughs in cardiology, oncology, hypertension, and acute care medicine. *World Journal of Applied Medical Sciences, 2*(11), 18–29.
27. Sikkander, A. M., Abuelmakarem, H. S., & Meena, M. (2025). AI beneath: Innovations driving breakthroughs in cardiology, oncology, hypertension, and acute care medicine. *World Journal of Applied Medical Sciences, 2*(11), 7–17.
28. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). Current developments in cyclophosphamide for lymphoma:

Immunomodulation, metronomic approaches, and toxicity control. *World Journal of Applied Medical Sciences, 2*(11), 4–6.

29. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). Glucocorticoid administration is significantly associated with worse progression-free survival (PFS) in NSCLC: A meta-analysis. *World Journal of Applied Medical Sciences, 2*(11), 1–3.
30. Sikkander, A. M., Yadav, C. H., & Revanuri, N. (2025). Recent trends in Oncovin (vincristine) use for acute lymphoblastic leukemia: Liposomal formulations, pharmacogenomics, and toxicity-mitigation strategies. *ISAR Journal of Medical and Pharmaceutical Sciences, 3*(11), 20–23.
31. Sikkander, A. M., RamaNachiar, R., & Yasmeen, K. (2022). Artificial neural networks (ANNs) in lung cancer detection. *International Journal of Scientific Research and Innovative Studies, 1*(1).
32. Sikkander, A. M., RamaNachiar, R., & Yasmeen, K. (2022). Spiking neural network (SNN) using to detect breast cancer. *International Journal of Scientific Research and Innovative Studies, 1*(1), 20–22.
33. Sikkander, A. R. M. (2025). Ruthenium organometallic compounds in cancer treatment. *Biomedical Engineering: Applications, Basis and Communications, 37*(1), 2430003.
34. Sikkander, A. R. M. (2024). Organometallic osmium compounds in cancer therapy. *International Journal of Advanced Molecular Engineering, 1*(2), 1–25.
35. Sikkander, A. R. M., Vedhi, C., & Manisankar, P. (2012). Electrochemical determination of calcium channel blocker drugs using multiwall carbon nanotube-modified glassy carbon electrode. *International Journal of Industrial Chemistry, 3*(1), 29.
36. Sikkander, A. R. M., Vedhi, C., & Manisankar, P. (2011). Electrochemical stripping studies of amlodipine using MWCNT modified glassy carbon electrode. *Chemical and Materials Research, 1*, 1–7.
37. Sikkander, A. M., Vedhi, C., & Manisankar, P. (2016). Utilization of sodium montmorillonite clay for enhanced electrochemical sensing of amlodipine. *Indian Journal of Chemistry, 55*, 571–575.
38. Sikkander, M., Vedhi, C., & Manisankar, P. (2012). Cyclic voltammetric determination of 1,4-dihydropyridine drugs using MWCNTs modified glassy carbon electrode. *Der Chemica Sinica, 3*, 413–420.
39. Sivakumar, R., Gopalakrishnan, P., & Abdul Razak, M. S. (2022). Comparative analysis of anti-reflection coatings on solar PV cells through TiO_2 and SiO_2 nanoparticles. *Pigment & Resin Technology, 51*(2), 171–177.
40. Tripathi, S. L., Theivanathan, G., & Sikkander, A. R. M. (2025). Extensive sequence analysis: Revealing genomic knowledge throughout various domains. In *Computational intelligence for genomics data* (pp. 17–30).
41. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2025). Tungsten-based compounds: A new frontier in cancer diagnosis and therapy. *Journal of Applied Organometallic Chemistry, 5*(2), 149–167.
42. Yadav, C. H., Revanuri, N., & Sikkander, A. R. M. (2026). Organometallic compound's phototoxicity against cancer cells. *Biomedical Engineering: Applications, Basis and Communications, 38*(1), 2550020.
43. Mohamed Sikkander, M. K. Y., Kavitha, K., Ramanachiar, R., & Anitha, M. V. (2022). Hydro desulphurization of petroleum. *Petroleum Chemistry Industry International, 5*(3), 150–152.
44. RamaNachiar, R., & Yasmeen, K. (2022). *Assess of calcitonin against arthritis*.
45. RamaNachiar, R., & Yasmeen, K. (2022). *Artificial neural networks (ANNs) in lungs cancer detection*.
46. RamaNachiar, R., & Yasmeen, K. (2022). *Spiking neural network (SNN) using to detect breast cancer*.
47. Revathy, T. A., Kirupavathy, S. S., Jennifer, D. A., Sikkander, A. R. M., & Tripathi, S. L. (2026). Hydrogen production processes from renewable energy resources. In *Hydrogen energy systems: Advancing sustainable power solutions* (pp. 329–353).
48. Sasikala, M. S., Kavitha, D. K., Balu, M. T. N., & Sikkander, D. A. M. (2021). Efficacy of nanomaterials and nanotechnology in diagnosis and treatment of heart disease. *International Journal of Innovative Research in Science and Technology, 1*(4).
49. Sasireka, D. S., Revathy, T. A., Kirupavathy, S. S., Sikkander, A. R. M., & Tripathi, S. L. (2026). Hydrogen fuel cells: Technology and applications. In *Hydrogen energy systems: Advancing sustainable power solutions* (pp. 203–230).
50. Saravanan, K. G., Ramakrishnan, M., & Sikkander, A. M. (n.d.). *Code confusion and identity based access mechanism for generic mobile security solutions using mobile agents*.
51. Sikkander, A. (2022). *Duct cancer evaluation in situ—Review*. Zenodo.
52. Sikkander, A. M. (2020). Favipiravir is a broad-spectrum antiviral prescription famous to selectively block RNA-dependent RNA polymerase (RdRp) and SARS-COVID-19. *Journal of Bioanalytical Chemistry, 5*(4), 1–4.
53. Sikkander, A. M. (2022). *Intrathecal chemotherapy for blood cancer treatment*. Zenodo.
54. Sikkander, A. M. (2022). Oxidative desulfurization of petroleum. *International Journal of Thermodynamics, Chemical and Kinetics, 8*(2), 1–4.
55. Sikkander, A. M., & Abbas, H. S. (2021). A novel biosensor for pathogens diagnosis. *Journal of Clinical Bioanalytical Chemistry, 5*(4), 1–4.
56. Sikkander, A. M., & Yasmeen, K. (2021). *Global anesthesia and pain medicine*.
57. Sikkander, A. M., & Yasmeen, K. (2021). Review on green synthesis of positively charged biocompatible gold nanoparticles in water: Use of ascorbic acid as reducing agent. *Technology, 6*(2).
58. Sikkander, A. M., & Yasmeen, K. (2021). Review on nanotechnology persecute vital role of curative applications in medicinal field and its ailing effects. *Journal of Chemical Technology and Applications, 4*(1), 7–10.
59. Sikkander, A. M., & Yasmeen, K. (2020). Piezopotential properties in nanowire devices of ZnO. *Nanoelectronics and Nanomaterials Journal, 8*(4), 22–28.
60. Sikkander, A. M., Haseeb, M., & Yasmeen, K. (2024). *Biological synthesis, characterization, and therapeutic utility of Fusarium oxysporum silver nanoparticles*. SSR Preprints.

61. Sikkander, A. M., Hemavathy, N., & Mishra, S. R. (2022). *Tactile system for visually impaired people using embedded technology*.

62. Sikkander, A. M., Kavitha, K., Mishra, S. K., & Yasmeen, K. (2020). Exigency for use of nano material biosensors in diagnosis of disease. *Journal of Science and Technology, 5*(2), 25–31.

63. Sikkander, A. M., Kavitha, K., Sasikala, M. S., & Yasmeen, K. (2021). Distinctiveness of nanoparticles drug delivery in cancer. *Materials Science and Nanotechnology, 5*(5), 1–5.

64. Sikkander, A. M., Mishra, S. R., & Kavitha, K. (2022). Review on nanogold and nano silver for cervical cancer therapy. *Journal of Scientific Letters, 1*(4).

65. Sikkander, A. M., Mishra, S. R., & Yasmeen, K. (2022). Advancement of nonmaterial's in petroleum industrial applications and the challenges. *International Journal of Petrochemicals and Natural Gas, 2*(1), 39–43.

66. Sikkander, A. M., Murukesh, C., Hemavathy, N., & Sangeeta, R. (2024). *Smart notice board*.

67. Sikkander, A. M., Mishra, R. S., & Sikkander, M. (2020). Efficaciousness of substrate-integrated microelectrodes (SIAMs) in neuroscience. *Journal of Biomedical Imaging and Bioengineering, 4*(3), 1–5.

68. Sikkander, A. M., & Rodrigues, J. J. P. C. (2025). AI in breast, ovarian, and uterine cancer treatment: A revolution in genomics. *International Journal of Science, Engineering and Technology, 13*(6), 1–13.

69. Sikkander, A. M., & Rodrigues, J. J. P. C. (2025). AI in cancer treatment: Revolutionizing genomics. *International Journal of Scientific Research in Engineering Trends, 11*(6), 1–8.

70. Sikkander, A. M., Vedhi, C., & Manisankar, P. (2018). Multiwall carbon nanotube based electrochemical sensor for nitrendipine, an antihypertensive drug. *Indian Journal of Chemical Technology, 25*, 489–492.

71. Sikkander, A. R. M. (2026). Biomarker-guided induction of autotroph-dependent cell death in treatment-resistant cancers. *World Journal of Applied Medical Sciences, 3*(2), 28–36.

72. Sikkander, A. R. M. (2026). Biomarker-guided induction of disulfidptosis in SLC7A11-overexpressing tumors. *World Journal of Applied Medical Sciences, 3*(2), 37–48.

73. Sikkander, A. R. M. (2026). Engineering smart nanoparticles to simultaneously trigger apoptosis, ferroptosis, and pyroptosis in resistant tumors. *World Journal of Applied Medical Sciences, 3*(3), 12–23.

74. Sikkander, A. R. M. (2025). Nanoparticle enabled copper delivery for tumor selective induction of cuproptosis. *World Journal of Multidisciplinary Studies, 2*(10), 8–19.

75. Sikkander, A. R. M., Lakshmi, V. V., Theivanathan, G., & Radhakrishnan, K. (2024). *Multiresolution evaluation of contourlet transform for the diagnosis of skin cancer*. SSR Preprints.

76. Sikkander, A. R. M., Yadav, H., & Meena, M. (2024). Nickel (II) complex containing 5-acetyl-N-(adamantan-2-yl) thiophene-2-carboxamide as a derivative for the drug isoniazid. *Advanced Journal of Chemistry, Section A, 7*(5), 501–521.

77. Sikkander, M., & Mishra, S. R. (2026). ML models using single-cell sequencing to forecast chemotherapy resistance in breast cancer. *World Journal of Applied Medical Sciences, 3*(3), 35–48.

78. Sikkander, M. (2022). Bio desulfurization of petroleum. *Petroleum Chemistry Industry International, 5*(3), 153–155.

79. Sikkander, M., & Mishra, R. S. (2021). Carbon-based nanomaterials impacting in neuroscience. *Journal of Chemical Technology and Applications, 5*(1), 1–2.

80. Touati, R., Ferchichi, I., Messaoudi, I., Oueslati, A. E., Lachiri, Z., & Kharrat, M. (2020). *Journal of Cybersecurity and Information Management*.

81. Gupta, N. W. J. K., Sikkander, A. R. M., & Faizan, U. A. (2023). Appraisal, recent advancement, and impacts of nanomedicine in cardiac asthma. *Journal of Medical, Pharmaceutical and Allied Sciences, 12*(15), 6132–6138. https://doi.org/10.55522/jmpas.V12I5.5214

82. Yasmeen, K., & Sikkander, A. M. (2021). Progression of nanotools in neuroscience. *Journal of Science and Technology, 6*, 9–16.